Mezquita et al. evaluated whether pre-treatment NLR and lactate dehydrogenase (LDH) levels were associated with ICI resistance in a retrospective cohort of 466 NSCLC patients treated with PD1/PD-L1 inhibitors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.